youtube_live
Q2 2026 earnings • released • EPS met 0.00% • Revenue beat +11.88%
See resultschevron_right
GUD:TSE
Knight Therapeutics Inc
CA$9.76
arrow_upward
+2.74%(+0.26) 1D
Aug 7, 4:00:01 PM GMT-4 · CAD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GUD...
Open
CA$9.50
High
CA$9.85
Low
CA$9.48
Mkt. cap
958.66M
Avg. vol.
0.00
Volume
249.85K
P/E ratio
169.68
52-wk high
CA$10.17
52-wk low
CA$5.66
EPS
CA$0.06
Beta
-0.04
Shares outstanding
98.18M
No. of employees
830
Open
CA$9.50
High
CA$9.85
Low
CA$9.48
Mkt. cap
958.66M
Avg. vol.
0.00
Volume
249.85K
P/E ratio
169.68
52-wk high
CA$10.17
52-wk low
CA$5.66
EPS
CA$0.06
Beta
-0.04
Shares outstanding
98.18M
No. of employees
830
News stories
From sources across the web
Investing.com Australia
·
2 days ago
Earnings call transcript: Knight Therapeutics posts strong Q2 2026 growth By Investing.com
MarketBeat
·
3 days ago
Knight Therapeutics Q2 2026 Earnings Call Transcript
Profile
Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange, with a market capitalization of $1.02 billion as of August 2019. Wikipedia
About Knight Therapeutics Inc
CEO-
Employees830
Founded2014
HeadquartersMontreal, Quebec, Canada
SectorPharmaceutical industry
Websiteknighttx.com
AI content may include mistakes. Learn more